510(k) Report

510(k) · Cleared

Cleared

EVOLVE Nitric Oxide Delivery System

K242578510(k) SpecialCleared Jan 3, 2025127-day reviewClass II21 CFR 868.5165

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Mallinckrodt Manufacturing, LLC · MRN Apparatus, Nitric Oxide Delivery

Cleared on Jan 3, 2025 as substantially equivalent to K240410 (Malinckrodt Manufacturing, LLC, 2024) after a 127-day review. Its family tree reaches back 2 generations to 2023.

Decided
Jan 3, 2025
Review
127 days
Class
Class II
Product code
MRN
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K222930 (2023). No later device cites it as a predicate yet.

  1. Root · 2 generations backK222930 Evolve Nitric Oxide Delivery SystemMallinckrodt Manufacturing, LLC · 2023
  2. 1 generation backK240410 EVOLVE Nitric Oxide Delivery SystemMalinckrodt Manufacturing, LLC · 2024
  3. This deviceK242578 EVOLVE Nitric Oxide Delivery SystemMallinckrodt Manufacturing, LLC · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K222930Evolve Nitric Oxide Delivery SystemMallinckrodt Manufacturing, LLC2023—
−1K240410EVOLVE Nitric Oxide Delivery SystemMalinckrodt Manufacturing, LLC2024—
0 (this device)K242578EVOLVE Nitric Oxide Delivery SystemMallinckrodt Manufacturing, LLC2025—
FIG. 1 — Lineage of K242578, 2023–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MRN? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MRN device

  1. #1 K242374 ULSPIRA TS™ Nitric Oxide Therapy Systemscore 12.6 · 14 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K240410EVOLVE Nitric Oxide Delivery System
Summary page 6
…1 EVOLVE Nitic Oxide Delivery System Predicate Device(s) K240410 Description of Device The EVOLVE Nitric Oxide (NO) Delivery System (DS) is used for administration and…
Malinckrodt Manufacturing, LLC2024—
†K222930Evolve Nitric Oxide Delivery SystemMallinckrodt Manufacturing, LLC2023—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 2 years and passes through 2 companies; a new generation was cleared every 7 months on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All MRN devices

MRN Apparatus, Nitric Oxide Delivery: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · MRN

2in 2025

2007: 22008: 22009: 12010: 22011: 22012: 32013: 22015: 12018: 12020: 32022: 12023: 42024: 22025: 2
2007high 4 (2023) · low 0 (2014)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MRN

566in 2023

2012: 117 days median2020: 84 days median2023: 566 days median
2007high 566 (2023) · low 84 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MRN

2in 2025

2010: 22014: 12023: 12025: 2, 2 Class I2026 (partial year): 2
2007high 2 (2010) · low 0 (2007)2026

Class I (2 since 2007) Class II/III not classified

Adverse event reports per year · MRN

155in 2025

2007: 32008: 92009: 102010: 1552011: 552012: 242013: 322014: 792015: 1562016: 942017: 1062018: 1382019: 1442020: 1992021: 2212022: 1152023: 992024: 1382025: 155
2007high 221 (2021) · low 3 (2007)2025

MAUDE reports naming product code MRN, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20072—03
20082—09
20091—010
20102—2155
20112—055
20123117024
20132—032
20140—179
20151—0156
20160—094
20170—0106
20181—0138
20190—0144
20203840199
20210—0221
20221—0115
20234566199
20242—0138
20252—2 (2)155
20260—2—

What is it indicated for?

The Evolve DS (delivery system) delivers INOMAX® (nitric oxide for inhalation) therapy gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath. It uses a specially designed Injector Module, which enables tracking of the gas delivery system waveforms and the delivery of a synchronized and proportional dose of NO.…

Read the full statement (290 words)

The Evolve DS (delivery system) delivers INOMAX® (nitric oxide for inhalation) therapy gas into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath. It uses a specially designed Injector Module, which enables tracking of the gas delivery system waveforms and the delivery of a synchronized and proportional dose of NO. It may be used with ventilators and respiratory care devices for which the Evolve DS has been validated. The Evolve DS provides continuous integrated monitoring of inspired NO2 and NO with a comprehensive alarm system. The Evolve DS also provides monitoring and alarms for the drug delivery system.

The Evolve DS incorporates a battery that provides up to 4 hours of uninterrupted NO delivery in the absence of external power. The Evolve DS also incorporates an integrated electronic blender that functions as a backup delivery device to provide an adjustable INOmax dose with user supplied oxygen to a manual resuscitator or gas delivery system. The electronic blender incorporates a separate control and delivery pathway that serves as a redundant mechanism for nitric oxide delivery in the event of a main system fault.

The Evolve DS must only be used in accordance with the indications, contraindications, warnings and precautions described in the nitric oxide drug packaging inserts and labeling and is indicated for use in term and near-term (>34weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. The Evolve DS is indicated for a maximum of 14 days use. The primary targeted clinical setting is the Neonatal Intensive Care Unit (NICU), and secondary targeted clinical setting is the transport of neonates.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K242578: EVOLVE Nitric Oxide Delivery System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K242578

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026